Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records.

ABSTRACT:

Background

The ADME Core Panel assays 184 variants across 34 pharmacogenes, many of which are difficult to accurately genotype with standard multiplexing methods.

Methods

We genotyped 326 frequently medicated individuals of European descent in Vanderbilt's biorepository linked to de-identified electronic medical records, BioVU, on the ADME Core Panel to assess quality and performance of the assay. We compared quality control metrics and determined the extent of direct and indirect marker overlap between the ADME Core Panel and the Illumina Omni1-Quad.

Results

We found the quality of the ADME Core Panel data to be high, with exceptions in select copy number variants and markers in certain genes (notably CYP2D6). Most of the common variants on the ADME panel are genotyp

SUBMITTER: Oetjens MT 

PROVIDER: S-EPMC3725600 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature